GB1593598A - Tetranicotinic ester of papaveroline and process for the production thereof - Google Patents
Tetranicotinic ester of papaveroline and process for the production thereof Download PDFInfo
- Publication number
- GB1593598A GB1593598A GB21857/78A GB2185778A GB1593598A GB 1593598 A GB1593598 A GB 1593598A GB 21857/78 A GB21857/78 A GB 21857/78A GB 2185778 A GB2185778 A GB 2185778A GB 1593598 A GB1593598 A GB 1593598A
- Authority
- GB
- United Kingdom
- Prior art keywords
- papaveroline
- ester
- nicotinic
- characteristic
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Paperveroline derivative for the treatment of arteriopathies, which is easily soluble in water and having the formula: <IMAGE> The invention also concerns the relevant production process, which involves reacting nicotinoyl chloride hydrochloride with papaveroline.
Description
(54) TETRA-NICOTINIC ESTER OF PAPAVEROLINE AND PROCESS
FOR THE PRODUCTION THEREOF
(71) We, SCHARPER S.p.A. PER L'INDUSTRIA FARMACEUTICA, an Italian
Joint-Stock Company, of Via Montenapoleone, 27, 20121 Milan, Italy, do hereby declare the invention for which we pray that a patent may be granted to us and the method by which it is to be performed to be particularly described in and by the following statement:
The present invention concerns a novel derivative of papaveroline, having effective and long lasting pharmacological properties, and a process for preparing same.
Papaveroline is a known tetraphenol consisting of an isoquinoline nucleus and a benzene nucleus, condensed through a methylene bridge. Papaveroline can be easily prepared by the total demethylization of papaverine.
The therapeutic use of papaveroline is also known although such use is limited by its low solubility in water and other pharmaceutically acceptable solvents.
To overcome this disadvantage, it has been proposed to introduce a sulfonic acid group into the benzene ring and the sulfonated product thus obtained has been effectively used in the treatment of particular arteriopathic conditions.
A continuing object, in medicine, is to provide pharmaceutical compounds suitable for selective therapy, and having a controlled period of activity, commonly known as a 'fast-delayed' action.
Various suggestions have been made, for example, involving the use of metallic derivatives of low solubility or using particular excipients which permit the slow release of the active substance but these do not always give satisfactory results.
In accordance with the present invention it has been found that the tetra-nicotinic ester of papaveroline, i.e. the compound of the formula:
provides a 'fast-delayed' pharmaceutical action which is believed to be due to the fact that the esterified phenolic groups of the nicotinic acid belong to different nuclei, i.e. the isoquinoline nucleus and the benzene nucleus. Therefore their hydrolysis will take place at different rates and is dependent on the pH value of the hydrolysis medium.
It has been further discovered that, in the therapy of arteriopathic forms, the tetra-nicotinic acid of papaveroline combines the action of papaveroline with the action of nicotinic acid, with the advantage of operating not only upon the deep stratus, as is the case with papaveroline, but also upon the superficial and cutaneous 'status, which is characteristic of nicotinic acid.
The tetra-nicotinic ester of papaveroline can be obtained by the reaction of nicotyl chloride hydrochloride with papaveroline. The reaction is slightly exothermic and takes place preferably at 20-300C by the direct addition of the nicotyl chloride hydrochloride to a solution of papaveroline in pyridine.
The ester may be separated from the reaction mixture by dilution with water and ice followed by neutralization with sodium bicarbonate.
The precipitate, after separation, is washed with acetone and dried.
The raw product thus obtained may be purified by dissolving it in dioxane, filtering while hot, and allowing it to precipitate.
The ester, separated, washed and dried, has been identified by means of tests for papaveroline and nicotinic acid and, quantitatively, by spectrophotometric means.
The composition and the structure of the ester thus obtained have been confirmed by elemental analysis, N.M.R., I.R. and U.V. spectra, determination of the nicotinic groups, thin layer chromatography and melting point, as reported in detail in the following example.
Pharmacological tests, such as LD50, total and partial vascular resistances, central and partial vascular resistances, central and peripheric, deep level fluximetry, medial and superficial, cutaneous thermometry and acute and chronic toxicity, have shown that:
a) the tetra-nicotine ester of papaveroline maintains unaltered, quantitatively, the pharmacodynamic characteristics of the components of the ester, i.e., papaveroline and nicotinic acid;
b) the nicotinic activity shows itself as soon as the ester is administered and continues for 6-12 hours;
c) the cutaneous hyperemia, due to the nicotinic action, is less pronounced, as compared to those compounds in which the nicotinic acid is in a free state or in the form of a salt, but, as compared to the latter, presents a more prolonged action (fast-delayed action):
d) on an equal weight basis, the ester shows a lower toxicity than that of the two components administered separately.
As can be seen above, it is evident that the nicotinic radicals are not hydrolysed and therefore freed at the same moment but rather at separate times, thus obtaining the desired "fast-delayed" action.
The present invention is further illustrated by the following example.
EXAMPLE
A) - Preparation of the nicotyl chloride hydrochloride
In a 500cc round-bottom flask, equipped with a reflux condenser, there is heated under reflux conditions and under anhydrous conditions for 3 hours 60.5g (0.5 mol) of nicotinic acid with 300g (2.5 mol) of SOC12.
The acid dissolves rapidly and, when the solution is complete, the hydrochloride acid addition salt of nicotyl chloride begins to precipitate. After allowing the reaction mixture to stand for one hour, the excess of SOCK2 is removed by distillation under reduced pressure and the solid residue is washed repeatedly with petroleum ether and placed in a desiccator.
B) - Preparation of the tetranicotinic ester of papaveroline
In a 500cc three-necked round-bottom flask, equipped with stirrer, reflux condenser and thermometer, there is dissolved 15g (0.078 mol of papaveroline in 500cc of pyridine.
Maintaining the temperature between 20-30"C, there is slowly added 43g (0.2415 mol) of the nicotyl chloride hydrochloride prepared in part A).
As the latter dissolves only slowly it is necessary to maintain a strong stirring action.
The mixture is allowed to react for 8 hours at ambient temperature and it is then heated for one hour at 600C to complete the reaction.
After cooling, the reaction mixture is poured into water and ice and the solution is neutralized with sodium bicarbonate.
After filtration, the precipitate is washed with acetone and dried. There is thus obtained 23g of product.
The 23g of the raw product are then dissolved under reflux conditions in 200cc of
dioxane, filtered while hot and the solution allowed to stand for a long period to obtain a precipitate.
There is obtained 18.5g of crystallized product with a yield of 50%.
Reaction scheme
The product thus obtained is a white crystalline powder, insoluble in water, methanol, ethanol and soluble in dioxane.
Its characteristics change after prolonged treatment with acid and alkaline solutions.
The ester hydrolyzes in acid and alkaline environments; the hydrolytic reaction involves the reaction of 4 molecules of water; from one mole of tetranicotinate there are obtained 4 mols of nicotinic acid and one mole of papaveroline.
Such process permits the qualitative and quantitative determination of the components of the ester.
The ester, after recrystallization from dioxane, shows a melting point of 214-215"C.
The compound, dried to constant weight in an oven at 110 C, gave the following analytical values:
Found: C : 67.97%; H : 3.68%; N : 10.12.% corresponding to an empirical formula: C40H25O8N5.
The calculated values are: C : 68.28%; H : 3.55%; N : 9.96% which agree fully with the experimental values.
Thin-layer chromatography was performed on a glass plate 5x20 coated with a 0.2mm layer of silica gel : GF 254 Merck (Registered Trade Mark). Activation was at 1200C for 1 hour with a development time 180 min. Travel was 10 cm. The eluent was a mixture of:
60% n-butanol
20% acetic acid (96%)
20% water
The determination was made under U.V. light of 360 mll while 0.1-0.2 cc of a 0.2% solution in dioxane of the tetranicotylpapaveroline obtained above is deposited as a spot on the above-described glass plate.
After development, on the plate there is observed an oblong spot of blue/purplish color having an Rf of 0.62.
Leaving the plate exposed to the air at ambient temperature, the spot assumes a yellow-brown coloration.
To confirm the pressure of 4 nicotinic groups, the following procedure was followed.
In a 250cc round-bottom flask equipped with a stopcock-controlled funnel, reflux condenser and thermometer there was introduced 0.12-0.15g of the product.
In the reaction flask there are introduced 150 ml. of 85% phosphoric acid (equivalent to 155g) and 20 ml. of water.
It is then heated over a direct flame controlling initially the rate of heating: when the temperature inside the flask reaches 1600C, there is added through the funnel 50 ml. of water at the rate of 6 drops per minute. The mixture is then heated to the boiling point for 30 minutes.
The mixture is allowed to cool and it is titered potentiometrically with 0.1 N NaOH, 1 ml of 0.1 N NaOH corresponding to 0.01231g of CsH4N-COOH.
We have used 0.1246g of tetranicotinic ester; there have been utilized 7.05 ml of 0.1N
NaOH. Found: 0.08678g; theorical: 0.08678; error: minus 0.14%.
The ester has therefore been assigned the following structure: 6,7-dinicotinoxy-1-(3' ,-4'-dinicotinoxybenzyl) isoquinoline, i.e.
Empirical formula: C40H250sN5 M.W.: 705.708
Papaveroline base: 39.57%
Nicotinic acid: 60.33%
U.V. Spectrum
The compound presents, in dioxane, two significative maxima: at 231 mF ( = 57000 + 1%) characteristic of the nicotinic nucleus, at 258 mF ( E =28000 + 1%). practically referrable to the papaverolinic nucleus (papaveroline base max. ass. 250 m,u in 1 N HC1).
The drop in the maximum is probably due to the different solvents employed.
The presence of maximum absorptions in the U.V. permits determination of the concentration of the compound by spectrophotometric methods.
The l.R. spectrum of the ester in suspension in Nujol (Registered Trade Mark) presents zones of absorption at 1740 cm-lm characteristic of the ester group C=O; at 1590 cm-l, characteristic of the groups C=C and C=N; and at 1225-1070 cm- , characteristic of the 1,2,3,4 substituted nucleus.
The NMR spectrum (in chloroform) is very complex: in fact, since the ester, unlike papaveroline, is insoluble in dimethylsulfoxide it is difficult to make an exact evaluation of the NMR data. However, the ratio of aromatic protons to benzylic protons is determinable at 11.56 (theoretical 11.5) in good agreement with the theoretical structure of the tetranicotinate.
WHAT WE CLAIM IS:
1. The tetra-nicotinic ester of papaveroline, i.e. a compound of the formula:
2. A process for the preparation of the tetra-nicotinic ester of papaveroline which comprises reacting nicotyl chloride hydrochloride with papaveroline.
3. A process as claimed in claim 2, wherein the reaction is conducted at a temperature of from 20 to 30"C.
4. A process as claimed in claim 2 or 3, wherein the product is isolated from the reaction mixture by diluting said mixture with water and ice and subsequently neutralizing the resulting mixture with sodium bicarbonate.
5. A process as claimed in claim 2, 3 or 4 wherein the papaveroline reactant is fed to the reaction vessel as a solution in pyridine.
6. A process as claimed in any one of claims 2-5, wherein the raw product is purified by crystallization from dioxane.
**WARNING** end of DESC field may overlap start of CLMS **.
Claims (8)
1. The tetra-nicotinic ester of papaveroline, i.e. a compound of the formula:
2. A process for the preparation of the tetra-nicotinic ester of papaveroline which comprises reacting nicotyl chloride hydrochloride with papaveroline.
3. A process as claimed in claim 2, wherein the reaction is conducted at a temperature of from 20 to 30"C.
4. A process as claimed in claim 2 or 3, wherein the product is isolated from the reaction mixture by diluting said mixture with water and ice and subsequently neutralizing the resulting mixture with sodium bicarbonate.
5. A process as claimed in claim 2, 3 or 4 wherein the papaveroline reactant is fed to the reaction vessel as a solution in pyridine.
6. A process as claimed in any one of claims 2-5, wherein the raw product is purified by crystallization from dioxane.
7. A process as claimed in Claim 2 substantially as hereinbefore described in the
foregoing Example.
8. The compound claimed in Claim 1 when prepared by a process as claimed in any one of Claims 2 to 7.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT24141/77A IT1143667B (en) | 1977-05-30 | 1977-05-30 | PARAVEROLINIC DERIVATIVE WITH A DURABLE ACTION AND PROCEDURE TO OBTAIN IT |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1593598A true GB1593598A (en) | 1981-07-22 |
Family
ID=11212187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB21857/78A Expired GB1593598A (en) | 1977-05-30 | 1978-05-24 | Tetranicotinic ester of papaveroline and process for the production thereof |
Country Status (13)
Country | Link |
---|---|
JP (1) | JPS53149982A (en) |
BE (1) | BE867515A (en) |
BR (1) | BR7803416A (en) |
CA (1) | CA1084504A (en) |
CH (1) | CH633446A5 (en) |
DE (1) | DE2822186A1 (en) |
ES (1) | ES470343A1 (en) |
FR (1) | FR2392987A1 (en) |
GB (1) | GB1593598A (en) |
GR (1) | GR63731B (en) |
IT (1) | IT1143667B (en) |
MX (1) | MX5515E (en) |
PT (1) | PT68115A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI77027C (en) * | 1979-07-19 | 1989-01-10 | Andre Buzas | SAFETY PREPARATION OF PHARMACOLOGICAL VERKS 1- / 1- (3,4-DIMETOXIFENYL) -3-AMINO-PROPYL / -6,7-DIMETOXY-Isoquinoline INFOERING. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1175246B (en) * | 1959-12-14 | 1964-08-06 | Orsymonde Fa | Process for the preparation of dimethylpapa-verolin-bis-nicotinic acid ester and its acidic dimaleate |
FR794M (en) * | 1960-12-02 | 1961-09-11 |
-
1977
- 1977-05-30 IT IT24141/77A patent/IT1143667B/en active
-
1978
- 1978-05-20 DE DE19782822186 patent/DE2822186A1/en not_active Withdrawn
- 1978-05-24 GB GB21857/78A patent/GB1593598A/en not_active Expired
- 1978-05-26 BE BE188060A patent/BE867515A/en not_active IP Right Cessation
- 1978-05-29 GR GR56361A patent/GR63731B/en unknown
- 1978-05-29 MX MX787104U patent/MX5515E/en unknown
- 1978-05-29 BR BR7803416A patent/BR7803416A/en unknown
- 1978-05-30 ES ES470343A patent/ES470343A1/en not_active Expired
- 1978-05-30 JP JP6483078A patent/JPS53149982A/en active Granted
- 1978-05-30 FR FR7816137A patent/FR2392987A1/en active Granted
- 1978-05-30 CH CH587778A patent/CH633446A5/en not_active IP Right Cessation
- 1978-05-30 CA CA304,384A patent/CA1084504A/en not_active Expired
- 1978-05-30 PT PT68115A patent/PT68115A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR7803416A (en) | 1979-01-02 |
FR2392987B1 (en) | 1982-04-23 |
CA1084504A (en) | 1980-08-26 |
GR63731B (en) | 1979-12-04 |
CH633446A5 (en) | 1982-12-15 |
PT68115A (en) | 1978-06-01 |
MX5515E (en) | 1983-09-14 |
FR2392987A1 (en) | 1978-12-29 |
ES470343A1 (en) | 1979-01-01 |
DE2822186A1 (en) | 1978-12-14 |
JPS572715B2 (en) | 1982-01-18 |
JPS53149982A (en) | 1978-12-27 |
IT1143667B (en) | 1986-10-22 |
BE867515A (en) | 1978-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cain et al. | Potential antitumor agents. 16. 4'-(Acridin-9-ylamino) methanesulfonanilides | |
CN110092745B (en) | Compound containing aromatic ring and application thereof | |
CN112920131A (en) | 1,2, 4-triazole derivatives and preparation method and application thereof | |
CN110092740B (en) | Fused ring compound and application thereof | |
JP2022517280A (en) | Bruton's tyrosine kinase inhibitor | |
SU683617A3 (en) | Method of the preparation of 1-nitro-9-dialkylamineisoalkylamineacrydines or their salts | |
DE2809720C2 (en) | ||
CN114105822A (en) | Pseudo C2Symmetrical chiral diallyl substituted compound and preparation method and application thereof | |
US3316266A (en) | 3-aminopyrazinoic acid derivatives and process for their preparation | |
US2924599A (en) | Derivatives of 1:3:5-triazanaphthalene | |
HRP20010747A2 (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
CN110240598B (en) | Process for preparing carboxamide derivatives and intermediate compounds thereof | |
GB1593598A (en) | Tetranicotinic ester of papaveroline and process for the production thereof | |
Robison et al. | The Rearrangement of Isoquinoline-N-Oxides. II. Observations with N-Hydroxyisocarbostyrils and Other Substituted Derivatives1 | |
Parker et al. | Substituted 2-Picolines Derived from 6-Amino-2-picoline1 | |
US3585214A (en) | Hydroxyl derivatives of coumarine and processes for the preparation thereof | |
NO179517B (en) | Process for the preparation of 8-chloroquinolone derivatives | |
US3872108A (en) | Novel chromone derivatives and the production thereof | |
JPH0374671B2 (en) | ||
CN112679430B (en) | Method for preparing isoquinolinones compound | |
WO2002085858A1 (en) | Process for producing purified piperidine derivative | |
JPS5811874B2 (en) | Pyrido (3,4-D) Pyridazine Luino Seizouhou | |
US3268511A (en) | 5, 5-diloweralkyl-4-omicron-lower alkyl-2, 3-cyclocarbonato-l-pyranosyl halides | |
SU1711674A3 (en) | Method for the synthesis of azonium spironortropanol ester | |
FI65996C (en) | FORM OF THERAPEUTIC PREPARATION OF NUTRITIONAL N-2-FURYLMETHYL) -5-SULFAMOYL-ORTANYL SYROR OR DERAS SALTER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
PCNP | Patent ceased through non-payment of renewal fee |